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men will respond to androgen deprivation  therapy for a 
finite time before ultimately progressing and succumbing to 
their disease. 
Bone targeted therapy has included bone-seeking 
radionuclides for nearly 30 years. The beta-emitting bone-
seeking radionuclides Strontium-89 and Samarium-153 EDTMP 
as well as Rhenium-186 HEDP and Rhenium-188 HEDP have 
been used to palliate pain in advanced cancer metastatic to 
bone for many years [2]. Despite clear evidence of benefit in 
palliation, these agents have never been shown to result in a 
survival benefit for patients.  
Radium-223 is the first in class alpha-emitting radionuclide 
which began clinical testing almost 10 years ago and has 
recently become licenced for the treatment of castration 
resistant pros-tate cancer (CRPC) metastatic to bone. In an 
international prospective randomised clinical trial, Radium-
223 (50kBq/kg, for 6 cycles at 4 weekly intervals) + best 
standard of care (BOS) was shown to improve overall survival 
compared to placebo + BOS in men with symptomatic, meta-
static CRPC. Radium-223 also resulted in significant 
improvement in time to symptomatic pro-gression [3].  
The rationale for combining External Beam Radiotherapy 
(EBRT) with Radium-223 in the treatment of metastatic 
prostate cancer will be discussed. In particular the potential 
for using Radium-223 along with advanced EBRT with 
‘curative’ intent in hormone naïve de novo metastatic 
prostate cancer will be described. 
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Throughout the past two decades the efforts to improve 
treatment efficacy for locally advanced head and neck 
squamous cell carcinoma (LA-HNSCC) have led to increased 
use of multimodality approaches combining surgery, 
radiotherapy (RT), and chemotherapy (CT). In fact, 
conventional RT  was associated with unsatisfactory patients’ 
outcomes, thereby a greater understanding of radiobiology 
led to the development of altered irradiation schedules, such 
as hyperfractionation (HF) and accelerated fractionation 
(AF), in the management of advanced HNSCC. Randomized 
controlled trials and meta-analyses demonstrated that for 
patients with locally advanced HNSCC, major improvements 
in loco-regional control and overall survival rates may be 
obtained by AF and HF with increased total radiation dose. 
CT represents an important component of multimodality 
treatment approach for locally advanced HNSCC. The 
combination of concurrent CT and RT (CCRT)  provides a 
substantial and statistically significant improvement in 
survival and loco-regional control, as compared to RT alone. 
CCRT has been also shown to preserve healthy tissue in 
almost two thirds of patients, without affecting survival. 
 However, despite hundreds of clinical trials in patients with 
advanced disease, there is no widespread consensus about 
patient selection for altered fractionation regimens, type of 
chemo-radiotherapy association, radiation/ chemotherapy 
dose schedule in LA-HNSCC. The state of the art of 
radiobiological models for tumor control and toxicity after 
CCRT will be presented together with methods of BED 
calculation. Model parameters will be introduced to be 
applicable to different chemotherapy schedules. The aim is 
to highlight the potential convenience of using radiobiology 
in the selection more effective treatment strategies. As 
secondary aim BED for combined CCRT with/without 
hyperthermia (HT) will be introduced to further stress the 
versatility of radiobiological concepts in predicting patient’ 
outcome and improving the efficacy of treatment strategies. 
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Particle therapy offers distinct physical properties leading to 
reduction of integral dose. For low-LET particles, biology is 
relatively comparable to photons, however, if this often cited 
sentence is correct in detail, is a matter of discussion. Albeit 
known heterogeneities and differences, altogether, the 
relative biological effectiveness (RBE) is postulated to be 
around 1.1. Proton therapy requires elaborate, large and 
expensive facilities, leading to a cost that is several times 
higher than advanced photon treatments. Treatment planning 
for particle therapy is delicate, special knowledge and 
training is necessary, and caution must be met at all steps. 
In spite of all these challenges, there is a strong rationale 
that the physical benefits of particle therapy convert into a 
clinical benefit for the patient. To date, however, no 
randomized trial has shown these benefits. For certain 
indications, the argument for proton therapy is evident, such 
as some skull base tumors, or pediatric patients, when timely 
proton treatment is available.  
Currently, with many centers worldwide, reserach foci are 
ongoing in different disease groups, as well as in terms of 
further pre-clinical assessment, to define the therapeutic 
window or proton therapy. 
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The first Scandinavian Proton Centre, Skandionkliniken, is 
planned to treat its first patient in June 2015; a facility 
owned by the seven regions with university hospitals. 
Patients will be referred to Skandionkliniken through these 
hospitals utilising “distributed competence” [1]. The patients 
will be prepared for treatment at their “home centre”; 
immobilisation, CT-scanning and treatment planning will be 
performed at the university hospital. All treatment plans will 
be reviewed at joint teleconference meetings [2] prior to the 
treatment start. The patient and any individual 
immobilisation device will be sent to Skandionkliniken for 
treatment. Skandionkliniken will be a “spot scanning only” 
facility.  
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In order to prepare for the clinical start and to train a group 
of medical physicists, dosimetrists and radiation oncologists, 
working in different centres and with different treatment 
planning systems, in proton treatment planning we started 
the Proton School in January 2012 [3,4]. We have had a 
couple one day face-to-face meetings with lectures and 
workshops, two four day courses and biweekly 
teleconferences. The purpose with the face-to-face meetings 
was to give everyone the same basic knowledge in proton 
treatment and planning. It also gave the students a chance to 
get to know each other, which eases the discussions during 
the teleconferences. Prior to the bi-weekly teleconferences 
the centres were expected to create treatment plans for 
selected patient cases in the proton TPS. Also, as preparation 
for these sessions relevant scientific articles were distributed 
for discussions in the group. During the teleconferences, the 
desktop of the proton TPS was shared for everyone to view 
and/or demonstrate. The teleconferences consist mainly of 
discussions about the suggested plan solutions, patient 
immobilisation, margins, dose distributions and plan 
robustness. The four-day courses were mainly directed to 
dosimetrists and physicists and jointly arranged with Varian 
and with clinical experts to increase the skills in treatment 
planning for protons. Many of the participants of the proton 
school, has also attended other courses, like the PSI winter 
school, ESTROs ion and proton course as well as PTCOG 
meetings and courses. 
Still we are faced with challenges; which patient groups do 
we treat in general, which do we start with? Thinking protons 
instead of photons has been the greatest challenge for the 
group as a whole. How do we create the best plan? This 
includes selecting robust beam angles and thinking about 
what the protons interact with on its way to the target 
volume. Discussions about target volumes has been frequent, 
as the use of them. Delineation is a major issue, not only for 
CTV/PTV but for other structures the protons might interact 
with in its beam path, as well as optimisation structures to 
provide the best plan and thereby “steer” the spots. 
The school has worked out well with active participation both 
in planning and discussing, helping each other in gaining 
experience in a field where we are novices. 
An important step is now to use and produce standardized 
treatment protocols, a treatment planning manual and other 
types of common instructions and check lists so that all seven 
centres create plans in the same technical manner. 
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Proton therapy is a high-precision radiotherapy technique. 
Since 1996,image guided proton therapy (IGPT) has been 
applied at PSI, using the spotscanning technique. Patients are 
positioned and imaged remotely at a dedicatedCT. In 
addition, the second generation Gantry 2 with an in-room 
sliding CT wastaken into operation in November of 2013. 
Fixation of the head is achieved bybite block or mask. In the 
prone position, we mold a special head support 
whichfacilitates a reproducible and comfortable position for 
fixation. In smallchildren, special care must be taken in 
forming the moulage to ensure that theairways are kept free.  
On a daily basis, a patient’spositioning is checked by means 
of orthogonal CT scout images. When theposition is correct, 
the patient is transported with a robotic transport systemto 
the treatment station, Gantry1, while maintaining the fixed 
position. 
We estimate that our remote patientpositioning method 
facilitates a patient throughput of up to 40% higher thanin-
room positioning, because the often time-consuming process 
of positioningand imaging takes place outside the treatment 
room.  
In addition, and in contrast tophoton therapy, proton therapy 
is very sensitive to range changes. It istherefore important 
that during the daily pre-treatment imaging process,changes 
in the patient’s anatomy (such as weight gain or loss) or body 
cavities(e.g. swelling due to sinusitis) need to be monitored 
and taken into account.  
Based on a comprehensive analysis of300 patients, it has 
been established that we achieve a positioning accuracy 
ofless than 2 mm for head and neck cases. 
After almost 20 years of clinicaloperation, the proton 
delivery system at PSI has proven its reliability. 
In the future, there will be a newchallenge: The spot 
scanning technique will be used with Gantry 2 for targetsin 
motion, as in the lung.  
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In developed countries, the total expenditures on health care 
have shown an almost continued increase over the last 
decades, and, not unexpectedly, the cost of cancer care has 
not been spared of this steady growth. The economic impact 
of health - and cancer - care can be measured as total 
spending, percent of national gross domestic product (GDP), 
or the cost to care for a single patient.  
In 2010, the European Union member states devoted an 
average of 9.0% of their GDP to health spending, a significant 
increase from the 7.3% spent in 2000, but a slight decline 
compared to the peak of 9.2% reached in 2009, consequence 
of the economic crisis affecting many countries as of the 
middle of 2008. In Europe, cancer care costs consume about 
5% of the global health care budget, ranging between 4.1% 
and 7%. To the best of our knowledge, radiotherapy only 
consumes bout 5% of the global cancer care budget. 
The variation in cancer care expenditures is more striking 
when focusing on the annual amount of money spent per 
capita: whereas the European average is 2,441€, some 
